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Clinical outcomes of Sodium-glucose cotransporter-2
inhibitors in patients with Type 2 Diabetes Mellitus:
An observational study from Pakistan
Bhagwan Das 1, Aisha Sheikh 2,
Bilal Ahmed 3, Najmul Islam 4
ABSTRACT
Objective: To determine the efficacy and safety of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use
in the Pakistani population.
Methods: Retrospective review of initial 100 patients who were prescribed with any agent of the SGLT2i
group from July 1, 2018 to January 2019 at Aga Khan University Hospital, Karachi. SGLT2i was offered
to patients of above 18 years of age with inadequate glycemic control on existing antidiabetic agents.
Changes in HbA1c, the Body Mass Index (BMI), serum creatinine, any decrease in the requirement of insulin
and sulphonylurea dose along with any side effects reported by the patients on follow-up visits.
Results: Most study participants were females (56%) with the mean age of 52±10 years. Substantial changes
were observed in the HbA1c (7.5±1.1%, 7.9±1.2% from 8.7±1.5%, p < 0.01), BMI (31.4±5.8, 31.8±5.8 from
32.4±5.9kg/m2, p < 0.01) and in creatinine (0.71±0.1, 0.75±0.1 from 0.79±0.1 mg/dl, p < 0.01) at three
and six months of follow up visits. The reduction in insulin and sulphonylurea doses was also significant.
Adverse drug events that led to drug discontinuation in 14 individuals were, Urinary tract infection (UTI)
(seven patients), Genital infection (three patients), nausea +UTI, abdominal pain +UTI, mild Diabetic
Ketoacidosis, and polyuria (one patient each). None reported Fournier’s gangrene, limb amputation, or
fracture.
Conclusion: SGLT2i significantly improved glycemic control, BMI, and serum creatinine in the Pakistani
population with a very low number of observed adverse events.
KEYWORDS: Glycated Hemoglobin A, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors,
Diabetes Mellitus, Type-2.
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Diabetes Mellitus is a serious public health
concern with a worldwide estimated prevalence
of 460 million in the adult population of age
between 20 to 79 years and 79.4% of this estimation
is living in low to middle-income countries
including Pakistan.1 In Pakistan estimated
prevalence of diabetes mellitus is about 17.1%1
with compliance of only 60 % with prescribed
anti diabetic medications.2 Diabetes mellitus
Type-2 (T2DM) is a slowly progressive metabolic
disorder characterized by insulin resistance and a
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progressive defect in insulin secretion associated
with severe macrovascular and microvascular
complications.3 Because of its progressive nature,
it needs multiple anti-diabetic agents for achieving
and maintaining optimum glycemic control,
unfortunately, more than 50 to 70% of patients
with T2DM failed to achieve and maintain their
glycemic control at some stage.4,5 Sodium-glucose
co-transporter 2 inhibitors (SGLT2i) are the new
oral agents for the management of T2DM that can
be used as an add on therapy with other oral agents
and insulin or as a monotherapy at any stage of
diabetes. These novel agents improve glycemic
control by inhibiting glucose reabsorption through
SGLT2 transmembrane proteins at the level of
proximal renal tubules and re-entering circulation.6
Selective inhibition of SGLT2 has shown a potent
antihyperglycemic effect with additional favorable
effects such as reduction in the weight and blood
pressure.7
Since the results of large trials on this group,
empagliflozin cardiovascular outcome event trial
(EMPA-REG OUTCOME), dapagliflozin effect on
cardiovascular events–thrombolysis in myocardial
infarction 58 (DECLARE-TIMI58) and canagliflozin cardiovascular assessment study (CANVAS),
it has been shown that these newer oral anti-diabetic agents reduce the incidence of cardiovascular
events in patients with T2DM and established cardiovascular disease,8-10 there has been great interest
of endocrinologists and cardiologists in expanding
use of this group of drug in T2DM patients with
cardiovascular diseases, especially heart failure.11
Empagliflozin and dapagliflozin are the two
FDA approved drugs of this SGLT2i group,
currently available in Pakistan. These both are
the recommended options for the management
of T2DM either as a monotherapy or as add-on
therapy with other antidiabetic agents 12 with a
reported improvement in HbA1c up to 1.8%.13 The
most common adverse effects reported with these
novel agents are genital infections (GIs) and urinary
tract infections (UTIs).
There is limited published data on the efficacy
and safety of both agents of this novel anti-diabetic
group, empagliflozin and dapagliflozin, among
the Pakistani population.14,15 Hence, we aimed
this study to know about the efficacy of SGLT2i in
terms of glycemic control and to report its effects
on other metabolic parameters like reduction in the
Body Mass Index (BMI) and change in the serum
creatinine level along with adverse effects on
Pakistani population in real-world practice.
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METHODS
This retrospective cohort study was conducted
at the outpatient clinics of the Endocrine section of
Aga Khan University Hospital Karachi (AKUH),
Pakistan. The Endocrine clinics of our hospital
cater more than 170 patients daily out of which
more than 90% are having T2DM.
We reviewed the outpatient records of all the
T2DM patients who were prescribed with any agent
of the SGLT2 inhibitors group (dapagliflozin or
empagliflozin) from 1st July 2018 to 31st January 2019,
due to failure to achieve adequate glycemic control
on their existing antidiabetic agents. The protocol of
this study was approved by the university’s ethical
committee (ERC number 2019-1034-2727, dated
February 19, 2019) and the study was carried out
under the Helsinki ethics principles. To preserve the
confidentiality of study participants, we coded each
participant and removed their personal details.
Data collection was started by reviewing
the files at Health Information Management
System (HIMS) of AKUH and was noted in the
predefined study questionnaire by the primary
author. We recorded the data regarding patients’
demographics including age, gender, antidiabetic
agents they were taking before starting SGLT2i,
baseline HbA1c, BMI, and serum creatinine level.
Inclusion and Exclusion criteria: We included the
patients who were of 18 years or older,of either
gender with insufficient glycemic control (HbA1c >
7%). We excluded all patients with T1DM, pregnant
women, or those planning to conceive, history of
recurrent UTI (with a frequency of at least three
UTIs/year or two UTIs in the last six months),
renal impairment, any malignancy, chronic liver
disease, on any medicine like steroids, antibiotics,
current or previous acute complications of diabetes
like hyperglycemic hyperosmolar state, diabetic
ketoacidosis (DKA), or any electrolyte imbalance.
The primary endpoint for our study was the
change in the HbA1c at three and six months
from baseline. Secondary endpoints were the
possible changes in the BMI, daily insulin and or
sulphonylureas (SU) dose, and serum creatinine
from baseline at three and six months of follow up
OPD visits. Safety was also assessed via reporting
of adverse drug events (AEs) on the basis of history
and lab evidence where appropriate. AEs of special
interest, UTI, GTI, volume depletion/hypotension,
diabetic ketoacidosis (DKA), electrolyte imbalance,
gangrene, spontaneous fracture, or any other
noted by the study participant.
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Table-I: Baseline clinical characteristics
of the study participants.
Age (years)

Table-III: Adverse Drug events
observed with SGLT2i.

51.9 ±10.4

Gender n (%)
Male

44 (44)

Female

56 (56)

BMI, kg/m2

32.4 ± 5.9

Creatinine

0.8 ± 0.1

Current treatment
Insulin takers (BB + premix)

49 (49%)

SU

32 (32%)

SU + Basal Insulin

9 (9%)

Others

10 (10%)

BB: Basal Bolus, SU: Sulphonylureas.

Statistical analysis: Mean±standard deviation
(SD) was calculated for the continuous variables,
percentages, and counts were calculated for the
nominal variables. To determine the changes in
baseline clinical characteristics according to the improvement in HbA1c, independent t-test was used
for continuous variables and Pearson’s chi-square
test was used for the categorical variables. We compared HbA1c, BMI at baseline, and at three and six
months using the paired t-test considering p-value
of <0.001 as statistically significant at a confidence
interval of 95%. All the statistical analysis was performed on SPSS version 19.0 (IBM Co., USA).
RESULTS
Among the Type-2 diabetic patients, initial
100 patients who were prescribed with SGLT2
inhibitors and who followed us on 3 and 6 months
as an outpatient were included in this study. The
mean age of the study participants was 52 years

ADE types

Percentage

None

86%

UTI

7%

Genital inflammation

3%

DKA

1%

Nausea and UTI

1%

Abdominal pain and UTI

1%

Polyuria

1%

and the majority (56%) were females. The average
duration of Diabetes was 12 years and the mean
BMI was 32.4 ±5.9kg/m2. About half (49%) of the
participants were insulin users and one-third (32%)
were on SU. Table-I.
After three months of SGLT2 intake, HbA1C
levels substantially improved from a baseline value
of 8.7 ± 1.5% to 7.9 ± 1.2% (P < 0.01). Likewise, BMI
decreased from 32.4±5.9kg/m2. kg/m2 at baseline
to 31.8±5.8 kg/m2 (P < 0.01) at 3-months. After six
months of SGLT2 treatment, HbA1C levels further
decreased at 7.5 ± 1.1 in comparison to baseline
measurements (P < 0.01). Similarly, the BMI of
the patients improved from 32.4±5.9kg/m2. kg/
m2 at baseline to 31.4±5.8kg/m2 at 6 months of
treatment. The average insulin requirement has
decreased from 93.5±55.8 IU at baseline to 85±49.3
IU at three months and then 81.4±47.7 IU at six
months (P < 0.01). Table-II and III.
DISCUSSION
This single-center 6 months study from Pakistan
shows SGLT2 inhibitors are effective in the Pakistani
population not only in glycemic control but also in

Table-II: Endpoints with changes at three and six months.
Variable

Baseline

3 months

6 months

p-value *

HbA1C

8.7 ± 1.5

7.9 ± 1.2

7.5 ± 1.1

< 0.01

BMI, kg/m2

32.4 ± 5.9

31.8 ± 5.8

31.4 ± 5.8

< 0.01

Creatinine

0.79 ± 0.1

0.75 ± 0.1

0.71 ± 0.1

< 0.01

Glimepiride (mg/day)

5.1 ± 2.4

4.2 ± 2.8

3.9 ± 2.9

0.01

Gliclizides (mg/day)

75 ± 37.9

58 ± 11.1

52.5 ± 43.1

0.01

93.5 ± 55.8

85 ± 49.3

81.4 ± 47.7

< 0.01

Medications
SU

Insulin (units /day)
Insulin
Baseline was taken as Reference.
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the weight reduction and other metabolic effects
with fewer side effects. Our study results further
strengthens the outcome data from the previous
studies,7,8,16 mostly done in the developed countries,
by showing significant improvement in different
metabolic parameters in the diverse population
with T2DM in the real-world setting in Pakistan.
Reduction in the HbA1c observed in this study,
from 8.7 ± 1.5% to 7.9 ± 1.2% at 3 months and further
reduction to 7.5 ± 1.1 at 6 months is comparable
to the results of other real world studies and trials
in which agents of this group were either used
in combination or as monotherapy and showed
improvement in HbA1c up to 1.8%.13-18 This
reduction in HbA1c and improvement in insulin
sensitivity and decrease in insulin resistance
along with a reduction in the beta-cell loss as
reported by Merocvi A, et al.19 make SGLT2i as
a potent agent to be used in combination or as
monotherapy as supported by EASD- ADA
position statement for DM management.20
Most patients with T2DM are obese or overweight
and weight loss in a diabetic patient is among the
desired outcome because of its impact on insulin
sensitivity, overall glycemic control, and long-term
morbidities.21 A decrease in the BMI noted in our
study is also comparable to other studies.16,18 We
found a decrease in BMI from 32.4 ±5.9 kg/m2
to 31.8±5.8 kg/m2 and 31.4±5.8 kg/m2 at 3 and 6
months respectively. Weight reduction associated
with SGLT2i likely observed is mainly because of
their glycosuria induced energy loss and reduction
in the fat mass was found to be sustained for more
than two years of treatment as reported by Bolinder
J et al.22 Because of this weight reduction and
improvement in BMI one can expect a decrease in
daily dose requirement of insulin and SU as seen
in this study and other clinical studies on this drug
group.16, 18, 23 This decrease in insulin and SU further
decreases the chances of weight gain and the risk of
hypoglycemia associated with both of these agents.
We observed a decrease in serum creatinine from
0.79±0.1 mg/dl to 0.71±0.1mg/dl and 0.75±0.1mg/
dl at 3 and 6 months. Evidence from different trials,
meta-analysis, systemic reviews, and real-world
studies has shown the renoprotective effect of
SGLT2Is, independent of their glycemic effects.24-26
They have been associated with a reduction in the
risk for major adverse renal outcomes among T2DM
patients and have also shown a decrease in the
progression of renal disease over a follow-up period
of 3.1 years.9 CANVAS program also reported a
reduction in the multiple renal outcomes up to 40%,
Pak J Med Sci
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including improvement in the estimated glomerular
filtration rate, eGFR and in the progression of
proteinuria, need for renal replacement therapy, or
mortality from renal causes.24
Treatment with SGLT2i in our study was
reasonably well tolerated; most common AEs
reported were urinary tract infections (7%) and
genital tract infections (3%), no events were severe,
were treated effectively along with discontinuation
of the drug. Incidence of UTIs reported in the
published clinical trials is also in a similar range,
from 4% to 9 % and the raw event rate of GTIs has
been reported around 4.7% in one recent metaanalysis by Liu et al.27 Given that SGLT2i are
reported to be associated with an enhanced risk of
UTI and GTI, further long term follow up studies
are warranted to confirm these findings.
Strengths & Limitations of the study: This is
among the first few real-world studies on the
efficacy and safety of SGLT2i from Pakistan with
promising results, showing this group of the
agent can be prescribed with confidence in our
population. Being a retrospective study, it has
some limitations in the collection of data, and, also
being a single-center study with a small sample
size, therefore, is not a true representation of the
whole Pakistani population.
CONCLUSION
Use of SGLT2i as add on therapy is effective in
the Pakistani population not only in improving
glycemic control but also leading to weight
reduction and with a decrease in daily doses of
sulphonylurea and insulin with a very low number
of observed adverse events.
Recommendation: Further prospective studies are
needed in this part of the world to report their
effects on cardiovascular, renal, and other chronic
complications of diabetes.
Conflict of interest: None.
Source of funding: None.
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